Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
CNY 25.56
(1.43%)
CNY 25.56
(1.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 143.28 Million CNY | 1.83% |
| 2022 | 140.7 Million CNY | -26.83% |
| 2021 | 192.29 Million CNY | -8.53% |
| 2020 | 210.22 Million CNY | -29.81% |
| 2019 | 299.51 Million CNY | -0.17% |
| 2018 | 300.03 Million CNY | -46.12% |
| 2017 | 556.9 Million CNY | 167.94% |
| 2016 | 207.84 Million CNY | 2.01% |
| 2015 | 203.74 Million CNY | 7.01% |
| 2014 | 190.39 Million CNY | 60.37% |
| 2013 | 118.72 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 37.92 Million CNY | -24.54% |
| 2024 Q1 | 50.26 Million CNY | 211.1% |
| 2024 Q3 | 39.72 Million CNY | 4.74% |
| 2023 FY | 143.28 Million CNY | 1.83% |
| 2023 Q3 | 67.88 Million CNY | -19.95% |
| 2023 Q2 | 84.8 Million CNY | 136.67% |
| 2023 Q1 | 35.83 Million CNY | 125.04% |
| 2023 Q4 | -45.24 Million CNY | -166.64% |
| 2022 Q2 | 42.65 Million CNY | -21.6% |
| 2022 Q1 | 54.4 Million CNY | 60.49% |
| 2022 FY | 140.7 Million CNY | -26.83% |
| 2022 Q4 | 15.92 Million CNY | -42.54% |
| 2022 Q3 | 27.71 Million CNY | -35.03% |
| 2021 Q2 | 39.25 Million CNY | -46.32% |
| 2021 Q1 | 73.12 Million CNY | 45.31% |
| 2021 Q3 | 46.01 Million CNY | 17.23% |
| 2021 Q4 | 33.9 Million CNY | -26.33% |
| 2021 FY | 192.29 Million CNY | -8.53% |
| 2020 FY | 210.22 Million CNY | -29.81% |
| 2020 Q4 | 50.32 Million CNY | 17.0% |
| 2020 Q2 | 79.72 Million CNY | 114.55% |
| 2020 Q1 | 37.15 Million CNY | -48.66% |
| 2020 Q3 | 43.01 Million CNY | -46.05% |
| 2019 Q3 | 59.61 Million CNY | -46.8% |
| 2019 Q1 | 55.46 Million CNY | -54.02% |
| 2019 FY | 299.51 Million CNY | -0.17% |
| 2019 Q4 | 72.38 Million CNY | 21.42% |
| 2019 Q2 | 112.04 Million CNY | 101.99% |
| 2018 Q2 | 69.97 Million CNY | 49.61% |
| 2018 FY | 300.03 Million CNY | -46.12% |
| 2018 Q4 | 120.64 Million CNY | 92.84% |
| 2018 Q3 | 62.56 Million CNY | -10.59% |
| 2018 Q1 | 46.76 Million CNY | -12.47% |
| 2017 FY | 556.9 Million CNY | 167.94% |
| 2017 Q3 | 41.43 Million CNY | 0.0% |
| 2017 Q4 | 53.43 Million CNY | 28.94% |
| 2016 FY | 207.84 Million CNY | 2.01% |
| 2015 FY | 203.74 Million CNY | 7.01% |
| 2014 FY | 190.39 Million CNY | 60.37% |
| 2013 FY | 118.72 Million CNY | 0.0% |